← Back to patent-cliff list
Sodium Oxybate Extended Release Oral Suspension (Avadel Pharmaceuticals)
Tier C — Watch / tradeSodium Oxybate Extended Release Oral Suspension (Avadel Pharmaceuticals)
Avadel Pharmaceuticals Plc
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Brand：ON-SXB, LUMRYZ
Indications (approved)：猝倒症, 发作性睡病, 过度嗜睡, 嗜睡
Regional status
US
Approved
2023-05-01
EU
No progress
2016-11-17
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sodium Oxybate Extended Release Oral Suspension (Avadel Pharmaceuticals)?
Approved indications include: 猝倒症, 发作性睡病, 过度嗜睡, 嗜睡.
When does the Sodium Oxybate Extended Release Oral Suspension (Avadel Pharmaceuticals) patent expire?
No public expiry year is available for Sodium Oxybate Extended Release Oral Suspension (Avadel Pharmaceuticals) yet; this page updates once verified.
How do I get a quote for Sodium Oxybate Extended Release Oral Suspension (Avadel Pharmaceuticals) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27